

# Isolated Canine Influenza H3N2 Virus for Vaccine Production



**INVENTORS • Kathy Toohey-Kurth, Jennifer Cooper, Francine Cigel**

**WARF: P150317US03**

Assigned to WARF as biological material.

**The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in isolated H3N2 influenza virus obtained from dogs infected during the 2015 outbreak in the Midwest.**

## OVERVIEW

According to the Centers for Disease Control, a canine influenza A H3N2 virus was responsible for an outbreak of dog flu reported in the Chicago area in 2015 that has since spread across 25 states. Testing by the Wisconsin Veterinary Diagnostic Laboratory (WVDL) has indicated that the strain is closely related to an Asian dog flu virus first detected in 2007 in South Korea.

Dog flu is a contagious respiratory disease that can spread rapidly in shelters and kennels. Symptoms range from mild (e.g., runny nose, cough) to severe, and sometimes can be fatal.

To date there is no evidence of transmission of canine flu viruses from dogs to humans.

## THE INVENTION

Researchers from the Wisconsin Veterinary Diagnostic Laboratory have obtained and identified isolated H3N2 influenza virus from canines that tested positive for influenza antigen during the 2015 epidemic. The virus has been amplified in eggs as well as cell culture (MDCK cells) for possible use in vaccine production.

These isolates were not previously shown to be circulating in the United States prior to 2015. They were originally identified from a canine nasal swab as influenza A at the WVDL, and the sample was then typed as an N2 strain using an in-house real-time PCR assay.

## THE WARF ADVANTAGE

Since its founding in 1925 as the patenting and licensing organization for the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.



## APPLICATIONS

- H3N2 canine influenza isolates for vaccine development

## KEY BENEFITS

- Readily available for licensing as a biomaterial

## STAGE OF DEVELOPMENT

Researchers at WVDL are currently completing a full genetic analysis and study of the virus.

## ADDITIONAL INFORMATION

### Related Technologies

[WARF reference number P160347US01 describes H3N2 influenza in cats and a potential vaccine.](#)

### Tech Fields

Veterinary - Companion animals

## CONTACT INFORMATION

For current licensing status, please contact Emily Bauer at [emily@warf.org](mailto:emily@warf.org) or 608-960-9842.

